---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-041053"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:57:03.293982+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ABVC licenses BLEX 404 to OncoX for pancreatic cancer; up to $13.75M in fees plus royalties

## Summary
- ABVC grants OncoX exclusive rights to develop/commercialize BLEX 404 for pancreatic cancer in 50% of worldwide markets for 20 years.
- OncoX to pay $6.25M (or 1.25M shares at $5) within 30 days; additional $0.625M milestone after next fundraising (no guarantee).
- ABVC entitled to 5% royalties on net sales, up to $12.5M; also may receive cash payments of at least $100K toward licensing fees.
- Press release states aggregate expected income of $13.75M and royalties up to $12.5M, but commercialization remains uncertain.
- Four FDA INDs approved for ABVC's oncology pipeline; ABV-1703 (BLEX 404) for pancreatic cancer.

## SEC filing metadata
- accession: 0001213900-24-041053
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/0001213900-24-041053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-041053
- JSON: https://secwatch.observer/filing/0001213900-24-041053.json
- Plain text: https://secwatch.observer/filing/0001213900-24-041053.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (effective 2024-05-08).
  - Action: entry
  - Agreement: license
  - Counterparty: OncoX BioPharma, Inc.
  - Value: $6,250,000
  - Effective: 2024-05-08
  source text: ompany entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/0001213900-24-041053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.